Hahn and colleagues already have evidence that similar modifications to p38, Src and some half-dozen other kinases also allow inducible activation of those enzymes' catalytic activities without ...

which suggests that distinct inter-subunit interactions occur that might enable separate mechanisms for allosteric activation and dephosphorylation protection by AMP binding. Tong and colleagues ...

“This is the second allosteric TYK2 inhibitor we have advanced into the clinic this year, after SUDO-286 which is progressing in two Phase 1 trials as a topical treatment for psoriasis.